Quantcast

Latest pulmonary function testing Stories

2014-05-06 08:34:07

WARRINGTON, Pa., May 6, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will report first quarter 2014 financial results on May 8, 2014 before the open of the U.S. financial markets. The Company will host a live teleconference and webcast at 9:00 a.m. Eastern Time that same day. During the conference call, Discovery Labs' management will discuss the 2014 first...

2014-04-30 20:23:46

LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse(TM) Ellipta(®) (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is GSK's first once-daily anticholinergic, a type of...

2014-04-30 12:30:17

- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF) RIDGEFIELD, Conn., April 30, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today that the first results from two highly anticipated Phase 3 trials in idiopathic pulmonary fibrosis (IPF) and in chronic obstructive pulmonary disease (COPD) will be presented at the 2014 American...

2014-04-28 08:32:52

RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro(TM) Ellipta(®) (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies...

2014-03-11 08:29:57

WARRINGTON, Pa., March 11, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will report fourth quarter 2013 financial results on Thursday, March 13, 2014 before the open of the U.S. financial markets. The Company will host a conference call and live audio webcast at 10:00 a.m. Eastern Time that same day. During the conference call, Discovery Labs' management will...

2014-01-13 16:25:12

-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema -- Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including...

2013-12-15 23:03:18

Available in the US just in time for the holidays, this specially constructed pulmonary harmonica helps improve breathing. No musical talent required, and there’s a coupon code below. Sarasota, FL (PRWEB) December 15, 2013 This year, buy something really useful for your loved ones. Developed for a family member with breathing problems, the Pulmonica is a pulmonary harmonica designed for nonmusicians that exercises the diaphragm and chest muscles to improve breathing. The low tuning is...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related